ABM: To study the expression of interferon-alpha/beta (IFN-α/β) receptor protein in liver of patients with hepatitis C virus (HCV)-related chronic liver disease and its clinical significance. METHODS: A total of 181...ABM: To study the expression of interferon-alpha/beta (IFN-α/β) receptor protein in liver of patients with hepatitis C virus (HCV)-related chronic liver disease and its clinical significance. METHODS: A total of 181 patients with HCV-related chronic liver disease included 56 with HCV-related liver cirrhosis (LC) and 125 with chronic hepatitis C (CHC). CHC patients were treated with five megaunits of interferon-α1b six times weekly for the first 2 weeks and then every other day for 22 wk. The patients were divided into interferon (IFN) treatment-responsive and non-responsive groups, but 36 patients lost follow-up shortly after receiving the treatment. The expression of IFN-α/β receptor (IFN-α/βR) protein in liver of all patients was determined with immunofluorescence. RESULTS: In liver of patients with HCV-related chronic liver disease, the expression of IFN-α/βR protein in liver cell membrane was stronger than that in cytoplasm and more obvious in the surroundings of portal vein than in the surroundings of central vein. Moreover, it was poorly distributed in hepatic lobules. The weak positive, positive and strong positive expression of IFN-α/βR were 40% (50/125), 28% (35/125), 32% (40/125), respectively in CHC group, and 91.1% (51/56), 5.35% (3/56), and 3.56% (2/56), respectively in LC group. The positive and strong positive rates were higher in CHC group than in LC group (P<0.01). In IFN treatment responsive group, 27.8% (10/36) showed weak positive expression; 72.2% (26/36) showed positive or strong positive expression. In the non-responsive group, 71.7% (38/53) showed weak positive expression; 28.3% (15/53) showed positive or strong positive expression. The expression of IFN-α/βR protein in liver was more obvious in IFN treatment responsive group than in non-responsive group. CONCLUSION: Expression of IFN-α/βR protein in liver of patients with HCV-related chronic liver disease is likely involved in the response to IFN treatment.展开更多
Nucleopolyhedrovirus(NPV) is divided into Group I and Group II based on the phy-logenetic analysis.It has been reported that Group I NPVs such as Autographa californica multiple NPV(AcMNPV) can transduce mammalian cel...Nucleopolyhedrovirus(NPV) is divided into Group I and Group II based on the phy-logenetic analysis.It has been reported that Group I NPVs such as Autographa californica multiple NPV(AcMNPV) can transduce mammalian cells,while Group II NPVs such as Helicoverpa armigera single NPV(HaSNPV) cannot.Here we report that AcMNPV was capable of stimulating antiviral ac-tivity in human hepatoma cells(SMMC-7721) manifested by inhibition of Vesicular Stomatitis virus(VSV) replication.In contrast,the HaSNPV and the Spodoptera exigua multiple NPV(SeMNPV) of group II had no inhibitory effect on VSV.Recombinant AcMNPV was shown to induce interferons al-pha/beta even in the absence of transgene expression in human SMMC-7721 cells,while it mediated transgene expression in BHK and L929 mammalian cells without an ensuing antiviral activity.展开更多
目的:探讨干扰素(IFN)-α/β受体启动子-408位点的单核苷酸多态性(SNP)与IFN疗效的关系。方法:应用聚合酶链反应(PCR)并基因测序法检测210例慢性乙型肝炎(CHB)患者(轻度38例、中度102例、重度70例)的IFN-α/β受体基因启动子-408位点的...目的:探讨干扰素(IFN)-α/β受体启动子-408位点的单核苷酸多态性(SNP)与IFN疗效的关系。方法:应用聚合酶链反应(PCR)并基因测序法检测210例慢性乙型肝炎(CHB)患者(轻度38例、中度102例、重度70例)的IFN-α/β受体基因启动子-408位点的SNP。对210例中既往未用过IFN治疗的80例CHB患者给予聚乙二醇化干扰素α-2a or 2b(Peg-IFN-α-2a/2b)治疗48周。比较SNP与Peg-IFN疗效的关系。结果:80例患者中,IFN治疗持久应答(SR)33例(41.3%),非持久应答(NSR)47例(58.7%)。IFN-α/β受体启动子-408位点CT基因型患者干扰素治疗SR为65%(13/20),显著高于CC基因型患者干扰素治疗SR 29.5%(13/44),两者比较差异有显著性意义(χ2=7.166,P=0.007)。干扰素治疗SR组IFN-α/β-408位点等位基因C、T的频率与NSR组的频率比较差异无显著性意义(P>0.05)。结论:IFN-α/β受体启动子-408为CT杂合基因型的CHB患者可能对Pec-IFN治疗效果较好。展开更多
Using flow cytometry analysis with human type Ⅰinterferons (IFN) (IFN α and β) and IFN α/β receptor antibody (ligand binding and antibody binding), we compared human IFN α/β receptor expressions on human H...Using flow cytometry analysis with human type Ⅰinterferons (IFN) (IFN α and β) and IFN α/β receptor antibody (ligand binding and antibody binding), we compared human IFN α/β receptor expressions on human H9 (T cells), Raji (B cells) and U937 (monocyte cells). The results indicated that H9, Raji and U937 cells all expressed IFN α/β receptor on their cell surfaces and the Raji cells showed the highest level of expression. The flow cytometry analysis using the antiserum to human IFN α/β receptor more clearly showed a strong IFN α/β receptor expression on Raji cells and a weak expression on H9 and U937 cells. These results indicate that B cells (Raji) expressed more receptor molecules on their cell surface than on T cells (H9) and on monocytes (U937), and the number of receptor molecules expressed on the cells is enough to be measured with flow cytometry.展开更多
文摘ABM: To study the expression of interferon-alpha/beta (IFN-α/β) receptor protein in liver of patients with hepatitis C virus (HCV)-related chronic liver disease and its clinical significance. METHODS: A total of 181 patients with HCV-related chronic liver disease included 56 with HCV-related liver cirrhosis (LC) and 125 with chronic hepatitis C (CHC). CHC patients were treated with five megaunits of interferon-α1b six times weekly for the first 2 weeks and then every other day for 22 wk. The patients were divided into interferon (IFN) treatment-responsive and non-responsive groups, but 36 patients lost follow-up shortly after receiving the treatment. The expression of IFN-α/β receptor (IFN-α/βR) protein in liver of all patients was determined with immunofluorescence. RESULTS: In liver of patients with HCV-related chronic liver disease, the expression of IFN-α/βR protein in liver cell membrane was stronger than that in cytoplasm and more obvious in the surroundings of portal vein than in the surroundings of central vein. Moreover, it was poorly distributed in hepatic lobules. The weak positive, positive and strong positive expression of IFN-α/βR were 40% (50/125), 28% (35/125), 32% (40/125), respectively in CHC group, and 91.1% (51/56), 5.35% (3/56), and 3.56% (2/56), respectively in LC group. The positive and strong positive rates were higher in CHC group than in LC group (P<0.01). In IFN treatment responsive group, 27.8% (10/36) showed weak positive expression; 72.2% (26/36) showed positive or strong positive expression. In the non-responsive group, 71.7% (38/53) showed weak positive expression; 28.3% (15/53) showed positive or strong positive expression. The expression of IFN-α/βR protein in liver was more obvious in IFN treatment responsive group than in non-responsive group. CONCLUSION: Expression of IFN-α/βR protein in liver of patients with HCV-related chronic liver disease is likely involved in the response to IFN treatment.
基金supported by the National Natural Science Foundation of China(Grant Nos.30325002,30470075)National Basic Research Priorities Program of China(Grant No.2003CB1140).
文摘Nucleopolyhedrovirus(NPV) is divided into Group I and Group II based on the phy-logenetic analysis.It has been reported that Group I NPVs such as Autographa californica multiple NPV(AcMNPV) can transduce mammalian cells,while Group II NPVs such as Helicoverpa armigera single NPV(HaSNPV) cannot.Here we report that AcMNPV was capable of stimulating antiviral ac-tivity in human hepatoma cells(SMMC-7721) manifested by inhibition of Vesicular Stomatitis virus(VSV) replication.In contrast,the HaSNPV and the Spodoptera exigua multiple NPV(SeMNPV) of group II had no inhibitory effect on VSV.Recombinant AcMNPV was shown to induce interferons al-pha/beta even in the absence of transgene expression in human SMMC-7721 cells,while it mediated transgene expression in BHK and L929 mammalian cells without an ensuing antiviral activity.
文摘目的:探讨干扰素(IFN)-α/β受体启动子-408位点的单核苷酸多态性(SNP)与IFN疗效的关系。方法:应用聚合酶链反应(PCR)并基因测序法检测210例慢性乙型肝炎(CHB)患者(轻度38例、中度102例、重度70例)的IFN-α/β受体基因启动子-408位点的SNP。对210例中既往未用过IFN治疗的80例CHB患者给予聚乙二醇化干扰素α-2a or 2b(Peg-IFN-α-2a/2b)治疗48周。比较SNP与Peg-IFN疗效的关系。结果:80例患者中,IFN治疗持久应答(SR)33例(41.3%),非持久应答(NSR)47例(58.7%)。IFN-α/β受体启动子-408位点CT基因型患者干扰素治疗SR为65%(13/20),显著高于CC基因型患者干扰素治疗SR 29.5%(13/44),两者比较差异有显著性意义(χ2=7.166,P=0.007)。干扰素治疗SR组IFN-α/β-408位点等位基因C、T的频率与NSR组的频率比较差异无显著性意义(P>0.05)。结论:IFN-α/β受体启动子-408为CT杂合基因型的CHB患者可能对Pec-IFN治疗效果较好。
文摘Using flow cytometry analysis with human type Ⅰinterferons (IFN) (IFN α and β) and IFN α/β receptor antibody (ligand binding and antibody binding), we compared human IFN α/β receptor expressions on human H9 (T cells), Raji (B cells) and U937 (monocyte cells). The results indicated that H9, Raji and U937 cells all expressed IFN α/β receptor on their cell surfaces and the Raji cells showed the highest level of expression. The flow cytometry analysis using the antiserum to human IFN α/β receptor more clearly showed a strong IFN α/β receptor expression on Raji cells and a weak expression on H9 and U937 cells. These results indicate that B cells (Raji) expressed more receptor molecules on their cell surface than on T cells (H9) and on monocytes (U937), and the number of receptor molecules expressed on the cells is enough to be measured with flow cytometry.
